GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Beneish M-Score

Cutia Therapeutics (HKSE:02487) Beneish M-Score : 7.00 (As of Mar. 30, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 7 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Cutia Therapeutics's Beneish M-Score or its related term are showing as below:

HKSE:02487' s Beneish M-Score Range Over the Past 10 Years
Min: 7   Med: 7   Max: 7
Current: 7

During the past 3 years, the highest Beneish M-Score of Cutia Therapeutics was 7.00. The lowest was 7.00. And the median was 7.00.


Cutia Therapeutics Beneish M-Score Historical Data

The historical data trend for Cutia Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Beneish M-Score Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Beneish M-Score
- - 7.00

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beneish M-Score Get a 7-Day Free Trial - - - 7.00 -

Competitive Comparison of Cutia Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Cutia Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutia Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's Beneish M-Score falls into.


;
;

Cutia Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cutia Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 5.8185+0.528 * 1.3535+0.404 * 0.8926+0.892 * 11.8592+0.115 * 0.4615
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.4324+4.679 * -0.927143-0.327 * 2.4716
=7.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was HK$107.6 Mil.
Revenue was HK$150.5 Mil.
Gross Profit was HK$77.7 Mil.
Total Current Assets was HK$1,549.1 Mil.
Total Assets was HK$1,866.9 Mil.
Property, Plant and Equipment(Net PPE) was HK$247.2 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$46.5 Mil.
Selling, General, & Admin. Expense(SGA) was HK$279.1 Mil.
Total Current Liabilities was HK$278.7 Mil.
Long-Term Debt & Capital Lease Obligation was HK$112.6 Mil.
Net Income was HK$-2,147.9 Mil.
Gross Profit was HK$0.0 Mil.
Cash Flow from Operations was HK$-417.1 Mil.
Total Receivables was HK$1.6 Mil.
Revenue was HK$12.7 Mil.
Gross Profit was HK$8.9 Mil.
Total Current Assets was HK$1,279.1 Mil.
Total Assets was HK$1,615.7 Mil.
Property, Plant and Equipment(Net PPE) was HK$268.2 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$21.1 Mil.
Selling, General, & Admin. Expense(SGA) was HK$54.4 Mil.
Total Current Liabilities was HK$86.4 Mil.
Long-Term Debt & Capital Lease Obligation was HK$50.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(107.576 / 150.529) / (1.559 / 12.693)
=0.714653 / 0.122824
=5.8185

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(8.864 / 12.693) / (77.667 / 150.529)
=0.698338 / 0.51596
=1.3535

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1549.137 + 247.203) / 1866.859) / (1 - (1279.113 + 268.178) / 1615.668)
=0.037774 / 0.042321
=0.8926

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=150.529 / 12.693
=11.8592

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(21.128 / (21.128 + 268.178)) / (46.468 / (46.468 + 247.203))
=0.07303 / 0.158231
=0.4615

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(279.093 / 150.529) / (54.431 / 12.693)
=1.854081 / 4.288269
=0.4324

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((112.626 + 278.682) / 1866.859) / ((50.585 + 86.436) / 1615.668)
=0.209608 / 0.084808
=2.4716

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-2147.917 - 0 - -417.071) / 1866.859
=-0.927143

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cutia Therapeutics has a M-score of 7.00 signals that the company is likely to be a manipulator.


Cutia Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutia Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.
Executives
Zhang Lele 2101 Beneficial owner
Zhang Qiping 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p. 2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Yf Dermatology Limited 2101 Beneficial owner
Yunfeng Capital Limited 2102 Investment manager
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you

Cutia Therapeutics Headlines

No Headlines